2 recruiting, 1 completed, 1 unknown. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 2, Completed 1, Unknown 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Won Seog Kim: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type Tislelizumab - Lymphoma | Phase 2 | Recruiting | Won Seog Kim | 38 | 2023-03-02 | 2024-04-03 |
| Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS) ACHOP - T Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Won Seog Kim | 41 | 2022-07-01 | 2023-10-23 |
| Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy Isatuximab, Cemiplimab - Natural Killer/T-cell Lymphoma, Relapsed Natural Killer/T-cell Lymphoma | Phase 2 | Completed | Won Seog Kim | 37 | 2021-06-25 | 2026-04-27 |
| [CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma Rituximab, Methotrexate, Cytarabine Injection - Primary CNS Lymphoma | Phase 2 | Unknown | Won Seog Kim | 35 | 2018-11-30 | 2020-10-22 |
Lymphoma (1) · Lymphoma, T-Cell (1)
Cytarabine (1) · Methotrexate (1) · Rituximab (1) · cemiplimab (1) · isatuximab (1) · tislelizumab (1)
South Korea (4)
Wonseog Kim, M.D (1) · Wonseog Kim, MD, Ph.D (1)